The respiratory disease drug developer has collected series A funding from investors including Shionogi to fund clinical trials of its lead drug candidate .

Vast Therapeutics, a US-based developer of respiratory disease therapies based on research at University of North Carolina (UNC) at Chapel Hill, has secured $15m in a series A round that included pharmaceutical firm Shionogi, Wral TechWire has reported.
The company revealed it had raised funding last month without giving a precise amount. It has also received a $300,000 award from non-profit organisation the Cystic Fibrosis Foundation to study the effects of chemical substances on living organisms.
Vast is…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?